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Abstract
Cardiomyopathies are a heterogeneous group of primary diseases of the myocardium,
including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhyth-
mogenic right ventricular cardiomyopathy (ARVC), with higher morbidity and mortality.
These diseases are genetically diverse and associated with rare mutations in a large num-
ber of genes, many of which overlap among the phenotypes. To better investigate the
genetic overlap between these three phenotypes and to identify new genotype–phenotype
correlations, we designed a custom gene panel consisting of 115 genes known to be associ-
ated with cardiomyopathic phenotypes and channelopathies. A cohort of 38 unrelated
patients, 16 affected by DCM, 14 by HCM and 8 by ARVC, was recruited for the study on the
basis of more severe phenotypes and family history of cardiomyopathy and/or sudden
death. We detected a total of 142 rare variants in 40 genes, and all patients were found to be
carriers of at least one rare variant. Twenty-eight of the 142 rare variants were also predicted
as potentially pathogenic variants and found in 26 patients. In 23 out of 38 patients, we
found at least one novel potential gene–phenotype association. In particular, we detected
three variants in OBSCN gene in ARVC patients, four variants in ANK2 gene and two vari-
ants in DLG1, TRPM4, and AKAP9 genes in DCM patients, two variants in PSEN2 gene
and four variants in AKAP9 gene in HCM patients. Overall, our results confirmed that cardio-
myopathic patients could carry multiple rare gene variants; in addition, our investigation of
the genetic overlap among cardiomyopathies revealed new gene–phenotype associations.
Furthermore, as our study confirms, data obtained using targeted next-generation sequenc-
ing could provide a remarkable contribution to the molecular diagnosis of cardiomyopathies,
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Introduction
Inherited cardiomyopathies are a group of heart muscle diseases characterized by heteroge-
neous phenotypes, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy
(HCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC), with higher morbid-
ity and mortality [1, 2]. DCM, defined by the presence of left ventricular (LV) or biventricular
dilatation and systolic dysfunction in absence of hypertension, valvular disease, or coronary
artery disease [1, 2], is one of the leading causes of heart failure (HF) and sudden death (SD)
and represents the most common condition requiring a heart transplant [1, 2]. HCM, charac-
terized by increased LV wall thickness that is not solely explained by abnormal loading condi-
tions [3, 4], is the most common cause of SD in young, and is considered an important cause
of HF and embolic stroke secondary to atrial fibrillation [5, 6]. A diagnosis of ARVC is made
mainly based on functional and structural abnormalities of the right ventricle (RV), fibro-fatty
replacement of the myocardium, depolarization and repolarization alterations, arrhythmias
with left bundle branch block (LBBB) morphology, and family history, with no single gold
standard exam of diagnosis established to date [7]. ARVC represents one of the major causes
of SD in the young and athletes [8, 9]; rarely, RV or biventricular dysfunction leads to HF [10].
Phenotypic overlap between different cardiomyopathies has been well described, leading to
diagnostic uncertainty in some cases [11].
Over the past 20 years, substantial progress in the understanding of the genetic basis of car-
diomyopathies has been made [1–3, 12, 13]. Recent family screening studies showed that auto-
somal dominant inheritance was the predominant pattern of transmission up to 48% of DCM
cases; possibilities of X-linked, autosomal-recessive, and mitochondrial inheritance were less
common [14]. To date, genes that encode sarcomere, cytoskeleton, desmosomes, nuclear
envelop proteins, and ion channels have been found to be associated with DCM [15, 16], with
TTN being the most frequently associated gene [17]. Current studies show that up to 60% of
HCM patients exhibit an autosomal-dominant trait with mutations in genes mostly affecting
sarcomere proteins [3, 18–20]. Moreover, mutations in genes that encode Z-disc proteins or
intracellular calcium modulators have also been detected [3]. The classical inheritance pattern
of ARVC is autosomal-dominant with variable expression and age-related penetrance [21]. To
date, most of genes that have been found associated with the ARVC phenotype encode desmo-
somal proteins and cause disease in up to 50% of probands [12, 21]. However, non-desmo-
somal genes have also been implicated in ARVC development [12]. In addition to the genetic
heterogeneity, a wide genetic overlap has also been noted among different cardiomyopathic
phenotypes, and between these heart muscle disorders and channelopathies [22–29].
According to recent international guidelines, genetic testing is strongly recommended for
each patient with inherited cardiomyopathy to identify a causative mutation and subsequently
provide pre-symptomatic testing of relatives who are at risk of developing the same disease at a
later stage; moreover, some disease-causing gene mutations have been found to be associated
with more severe clinical features, presentation at an early age, overall poor prognosis, or
increased risk of SD [30–34]. Therefore, genetic testing can have considerable implications in
terms of early diagnosis, implementation of prognostic stratification algorithms, and timely
therapeutic interventions [32, 35].
Sanger sequencing is a standard technique of molecular diagnostics for disorders predomi-
nantly related to a single causative gene. However, this screening method is laborious. The
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high degree of genetic heterogeneity, with more than 100 cardiomyopathy-related genes iden-
tified to date, can be addressed more efficiently by high-throughput sequencing, referred to as
next-generation sequencing (NGS) [36], which includes targeted resequencing, whole exome
sequencing, and whole genome sequencing. Targeted enrichment appears to be the method of
choice in a clinical diagnostic setting, not only because it allows focusing on the genes relevant
to a particular disorder, thereby preventing unsolicited findings, but also because it provides a
superior quality of exon representation and coverage.
In this study, we developed a custom “pan-cardiomyopathy panel” containing 115 genes
known to be associated with DCM, HCM, and ARVC as well as to channelopathies. Based on
this panel, we performed molecular screening in 38 unrelated patients, 16 affected by DCM, 14
by HCM, and 8 by ARVC, to better investigate the genetic overlap between these three pheno-
types and to identify new gene–phenotype associations using the Illumina MiSeq platform.
Moreover, we investigated the possible role of genes linked to channelopathies in modifying
the clinical cardiomyopathic phenotype.
The results of this study put a spotlight on novel cardiomyopathic gene–phenotype associa-
tions, extending the mutational spectrum underlying cardiomyopathies. Furthermore, our
data suggest that some genes involved in channelopathies may act as genetic modifiers, modu-
lating the clinical features and severity of cardiomyopathic phenotypes, as well as contributing
to the variable cardiomyopathic phenotypic expression. Our findings support the “pan-cardio-
myopathy panel” approach, since many patients carried multiple rare variants in several genes.
Materials and methods
Ethics statement
All patients provided their written informed consent to participate in this study. We obtained
written consent from parents of the minors included in the study. The project conformed to
the principles of the Declaration of Helsinki (World Medical Association) and was approved
by the Ethics Committee of the University Hospital Consortium, Policlinico of Bari, Italy.
Study subjects, disease criteria, and clinical evaluation
The patients who were referred to the Cardiomyopathy Unit, Cardiology Unit, Department of
Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari (Italy), between
February 2008 and June 2014 were enrolled in this study. A total of 38 Italian unrelated pa-
tients (16 DCM, 14 HCM, and 8 ARVC) were recruited on the basis of more severe phenotypes
and family history of cardiomyopathy and/or SD (S1 Table).
All patients underwent clinical work-up, including medical history, physical examination,
12-lead electrocardiogram (ECG), transthoracic echocardiography, and 24-hour ECG moni-
toring. Where appropriate, exercise testing and coronary angiography were performed. Sub-
jects without contraindications, such as pacemaker, defibrillator, or severe claustrophobia,
underwent cardiac magnetic resonance imaging.
The diagnosis of DCM was according to the World Health Organization criteria [37] and
international guidelines [1, 38]. The exclusion criteria were previously described [39–41]. The
diagnosis of HCM was based on international criteria [42, 43]. The diagnosis of ARVC was
according to the original [44] and modified [45] Task Force criteria.
Gene panel design
The gene panel was designed using the Design Studio Tool (Illumina, San Diego, CA, USA).
The coding regions and intron–exon boundaries of 115 genes, known to be associated with
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DCM, HCM, and ARVC as well as channelopathies, were selected for targeted gene enrich-
ment. For genes with multiple transcripts, all exons included in transcripts expressed in car-
diac muscle were considered in the gene panel design. The coordinates of genomic regions
were based on NCBI build 37 (UCSC hg19). The complete list of genes and transcripts is
reported in S2 Table.
Targeted gene enrichment and high-throughput sequencing
Total DNA was extracted from peripheral blood samples using the Wizard Genomic DNA
Purification Kit (Promega, Mannheim, Germany) according to the manufacturer’s instruc-
tions, quantified, and qualitatively checked using NanoDrop 2000c (Thermo Fisher Scientific,
Waltham, MA, USA).
Custom targeted gene enrichment and DNA library preparation were performed using the
Nextera Capture Custom Enrichment kit (Illumina) according to the manufacturer’s instruc-
tions. The targeted regions were sequenced using the Illumina MiSeq platform, generating
approximately two millions of 150-bp paired-end reads for each sample (Q3090%).
Sequencing and genotyping data were submitted to “The European Genome-phenome
Archive” EGA (http://www.nature.com/ng/journal/v47/n7/full/ng.3312.html), with the acces-
sion number EGAS00001002506. S3 Table reports the accession numbers of the sequencing
data for each patient.
Variant calling, filtering, and classification
Variant calling was performed using the web tool Online Deep Exome Sequencing Software
Analysis (ODESSA) [46]. The pipeline, after sequencing data submission, executed the follow-
ing steps: the quality checks and filter of the reads; the alignment on the reference genome
hg19; the variant preprocessing; the coverage statistics and metrics; the variant calling; the var-
iant annotation. Genetic variants predicted to alter the protein, such as non-synonymous vari-
ants, nonsense variants, canonical splicing site variants (affecting the donor or acceptor splice
sites), in-frame and frameshift insertion/deletions, supported by at least 10 reads, and with a
minor allele frequency (MAF) 0,4%, 0,2%, 0,05% for DCM, HCM and ARVC respec-
tively in variant databases, chosen considering the prevalence of the phenotypes in the general
population [47], were selected. To assess the potential functional impacts of variants, four
bioinformatics algorithms were used: PolyPhen-2 (PP2), Sorting Tolerant From Intolerant
(SIFT), Protein variation effect analyzer (Provean), and Mutation Taster. PhyloP and Phast-
Cons scores were also used to analyze the degree of sequence conservation of the mutated loci,
and Grantham’s score was considered to categorize codon replacements. To calculate these
three parameters for each rare missense variant, we employed Mutation Taster. Missense vari-
ants were considered “potentially pathogenic” if classified simultaneously as “damaging” by
SIFT, “deleterious” by Provean, “possibly” or “probably damaging” by Polyphen-2, and “Dis-
ease Causing” by Mutation Taster. TTNmissense variants were not considered potentially
pathogenic independently from the predictors’ results because, as recently reported, there is
no statistical difference in frequency between cases and controls and their potentially patho-
genic role can be established only by a segregation analysis in affected families [48, 49]. Stop-
gain and stoploss variants, splicing variants, frameshift, and in-frame insertions and deletions
were considered potentially pathogenic if classified as “Disease Causing” by Mutation Taster;
we defined these variant types as Radical variants. TTN truncating variants were considered
potentially pathogenic only if they affected TTN isoforms in the A-band region [49–51].
Variants not classified as potentially pathogenic by predictors, but for which a pathogenic
role was supported by published data [52] and/or by evidences in ClinVar and HGMD
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databases were considered as potentially pathogenic. Variants classified as Variants of Uncer-
tain Significance (“VUS”), “Likely Benign” or “Benign” in ClinVar database were not consid-
ered as potentially pathogenic variants (S1 Fig).
It should be considered that in our study the designation of potentially pathogenic variants
derived from a genetic test aimed to assess new gene-phenotype associations. The clinical rele-
vance of these potentially pathogenic variants should instead be assessed on the basis of the
current guidelines [53], but it was not the aim of the study.
Variant databases and prediction programs
Variant databases: 1000 Genomes Project (http://browser.1000genomes.org/index.html),
NCBI dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), NHLBI Exome Sequencing Project
(ESP) Exome Variant Server (http://evs.gs.washington.edu/EVS/), Genome Aggregation
Database (gnomAD; http://gnomad.broadinstitute.org), ClinVar (http://www.ncbi.nlm.nih.
gov/clinvar/), Human Genome Mutation Database (HGMD Professional 2014; http://www.
biobase-international.com/).
Prediction programs: PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT and Pro-
vean (http://provean.jcvi.org/protein_batch_submit.php?species=human), and Mutation
Taster (http://www.mutationtaster.org/).
Results
Clinical features
The clinical characteristics of all evaluated patients are shown in S1 Table.
A total of 16 DCM patients (14 men, 2 women; mean age 38 ± 15 years; range: 15 to 67
years) were included in this study, 11 of which had a family history of DCM and/or SD.
Fourteen patients (7 men and 7 women; mean age 35 ± 14 years; range: 16 to 58 years) pre-
sented with either obstructive (n = 7) or non-obstructive (n = 7) form of HCM, 10 of which
had a family history of the condition and/or SD.
Eight patients (5 men and 3 women; mean age 40 ± 21 years; range: 12 to 72 years) presented
with ARVC, 7 of which had a family history of arrhythmogenic cardiomyopathy and/or SD.
Overall, 31 patients out of 38 received an implantable cardioverter defibrillator (ICD), 24 of
which in primary prevention and 7 in secondary prevention; one DCM patient aged 45 years
underwent a heart transplant; and one DCM patient aged 71 years carrying an ICD died due
to refractory HF.
Pan-cardiomyopathy gene panel sequencing and variant calling
We designed a custom pan-cardiomyopathy panel containing 115 genes known to be associ-
ated with DCM, HCM, and ARVC, as well as to channelopathies (S2 Table). The custom gene
panel, encompassing all exons of each gene and splicing sites, was based on the Illumina strat-
egy of targeted enrichment of these regions. Using this custom panel, we performed genetic
screening of the 38 unrelated patients described above, obtaining an average of two millions of
150-bp paired-end reads per sample.
A total of 3286 missense variants, 18 nonsense variants, 23 splicing site variants, 29 in-
frame and 6 frameshift insertion/deletions were identified using the ODESSA pipeline, provid-
ing an average of 85 variants per DCM patient, 89 per HCM patient, and 92 per ARCV patient
(S4 Table). Overall, the mean read depth of coverage for these selected variants was 222X
(range, 12–565X). Variants that fulfilled the inclusion criteria described in the Materials and
Methods were annotated as rare variants and classified using standard nomenclature (S1 Fig).
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Variant assessment
In total, we detected 142 rare variants in 40 genes, of which 137 variants had a heterozygous
status and 5 variants on the X chromosome had a hemizygous status. Thirty-three (23,2%) of
these 142 rare variants were absent from both dbSNP and gnomAD (S5 Table). One hundred
and twenty-four rare variants were missense variants (87%), while 5 were frameshift insertion/
deletion variants, 3 in-frame insertion/deletion variants, 8 nonsense variants, and 2 involved a
splicing site (S6 Table). The TTN gene had the largest number of rare variants (42 variants),
followed by OBSCN (16 variants) and RYR2 (6 variants).
Considering rare variants for each cardiomyopathy type, in ARVC patients, the highest
number of rare variants was found in TTN and RYR2 genes (4 variants) followed by OBSCN
and PKP2 (3 variants) (S7 Table). For DCM patients, the highest number of rare variants was
found in TTN gene (26 variants), followed by OBSCN (8 variants) and ANK2 (4 variants) genes
(S8 Table). For HCM patients, the highest number of rare variants was found in TTN gene (12
variants), followed by OBSCN (5 variants) and MYBPC3 (4 variants) genes (S9 Table).
All patients carried at least one rare variant, while most of them (94.7%) carried more than
one rare variant; on average, 3.7 rare variants per patient (range, 1–9) were detected, with
DCM patients carrying the highest average number of rare variants (4.5 per patient), followed
by HCM (3.6 per patient), and ARVC (2.4 per patient) (S10 Table).
Of the 142 rare variants, 28 were classified as potentially pathogenic, 9 of which already
present in ClinVar and/or HGMD databases and/or supported by published data (Table 1
and S11 Table). Fifteen potentially pathogenic variants were missense mutations, 4 were
frameshift insertion/deletion mutations, 2 were in-frame insertion/deletion mutations, 5 were
nonsense mutations, and 2 affecting a splicing site (Table 1). We excluded from the list of the
potentially pathogenic variants, all the TTNmissense variants indicated as potentially patho-
genic by the analysis with the bioinformatics tools because, as recently reported, there is no sta-
tistical difference in frequency between cases and controls and their potential pathogenic role
can be established only by a segregation analysis in affected families [48, 49]. Regarding the
TTN truncating variants, we followed the recent evidences that suggest to consider as poten-
tially pathogenic only those variants affecting all TTN isoforms in the A-band region [50, 51].
We identified three TTN truncating variants in DCM patients. We considered as potentially
pathogenic only the TTN truncating variant V16477fs, referred to the N2B isoform (NM_
003319) as it maps in the TTN A-band region and was also not present in gnomAD database.
The R2490fs variant, referred to the Novex-3 transcript (NM_1333379) and the L24944X vari-
ant, referred to the N2B transcript (NM_003319) were not considered potentially pathogenic
as they mapped in the I and M-band regions of the TTN isoforms, respectively.
In twelve patients (310DCM, 365DCM, 968DCM, 1584DCM, 1669DCM, 1717DCM,
1838DCM, 1685HCM, 1798HCM, 1665ARVC, 1708ARVC and 1830ARVC), no potentially
pathogenic variant was identified, whereas 3 patients (76DCM, 1173HCM and 1776HCM)
carried two potentially pathogenic variants (Table 2 and S10 Table).
New gene–phenotype associations
Most of the rare variants identified in our study showed a well-established association with a
specific cardiomyopathic phenotype. In addition, in 23 of 38 patients, we found at least one
novel potential gene–phenotype association (Table 2 and S10 Table). As shown in Fig 1, con-
sidering the most represented genes, we found six new associations for AKAP9 gene, four for
ANK2 gene, three for DLG1, OBSCN and TRPM4 genes and two for PSEN2 and SYNE1 genes.
In particular, we focused on potentially pathogenic rare variants to examine the novel gene–
phenotype associations (Table 2 and S11 Table). For the ARVC phenotype, we found two
Expanded mutational spectrum in cardiomyopathies through targeted next-generation sequencing
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Table 1. Potentially pathogenic rare variants detected in our patients.
Gene Genomic
Position
Transcript Nucleotide Protein dbSNP MAF Cardiac
Phenotype
Supporting
evidences
ACTC1 chr15:35084392 NM_005159 c.707C>T S236F - - HCM GS, SI, PR,
PP2, MT, PC,
PP
AKAP9 chr7:91726576 NM_005751 c.10303C>T R3435X - - DCM MT
AKAP9 chr7:91737871 NM_005751 c.11610C>G Y3870X rs757753258 4.06x10-
6
HCM MT
DLG1 chr3:196812473 NM_004087 c.1915G>A G639R rs369412843 8.12x10-
6
HCM GS, SI, PR,
PP2, MT, PC,
PP
DMD chrX:32456458 NM_004009 c.3959G>A R1320H rs768990357 2.24x10-
5
ARVC SI, PR, PP2,
MT, PC, PP
DSP chr6:7569522 NM_004415 c.1524dupG V508fs - - DCM MT
DSP chr6:7580243 NM_004415 c.3820G>C A1274P - - DCM SI, PR, PP2,
MT, PP
LAMP2 chrX:119576454 NM_013995 c.928G>A V310I rs104894858 - HCM PP2, MT, PC,
PP, CV, HG
LMNA chr1:156100468 NM_170708 c.667_687dup L140_A146dup - - DCM REF
LMNA chr1:156106964 NM_170708 c.1549C>T Q517X - - DCM MT, PC, PP,
HG
MYBPC3 chr11:
47371475
NM_000256 c.506-2A>C - rs397516057 - HCM MT, PC, PP,
CV
MYBPC3 chr11:47369407 NM_000256 c.821+1G>A - rs397516073 2.98x10-
5
HCM MT, PC, PP,
CV, HG
MYBPC3 chr11:47367758 NM_000256 c.1090G>A A364T - - HCM SI, PR, PP2,
MT, PC, PP
MYBPC3 chr11:47360197 NM_000256 c.2182G>T E728X rs397515954 - HCM MT, PC, PP,
CV
MYH7 chr14:23895233 NM_000257 c.2102G>A G701D - - HCM SI, PR, PP2,
MT, PC, PP
MYH7 chr14:23886383 NM_000257 c.4498C>T R1500W rs45544633 - DCM SI, PR, PP2,
MT, CV, HG
MYH7 chr14:23884353 NM_000257 c.5410G>A A1804T rs730880818 4.06x10-
6
DCM SI, PR, PP2,
MT, PC, PP,
CV
NEXN chr1:78401657 NM_144573 c.1398_1400delAAT I467del - - HCM MT, PC
OBSCN chr1:228400286 NM_052843 c.802G>T E268X - - HCM MT, PP
OBSCN chr1:228525823 NM_001098623 c.16979C>T A5660V rs191098985 0.0006 DCM GS, SI, PR,
PP2, MT, PC,
PP
OBSCN chr1:228527758 NM_001098623 c.17371G>C A5791P rs200362121 0.0004 ARVC SI, PR, PP2,
MT, PC, PP
OBSCN chr1:228557681 NM_001098623 c.20006G>A R6669H rs373638525 9.4x10-5 DCM SI, PR, PP2,
MT, PP
PKP2 chr12:33030842 NM_004572 c.962_972delTCGGCCAGGCG V321GfsX11 - - ARVC MT
PKP2 chr12:32974392 NM_004572 c.2043delT I681fs - - ARVC MT,
RAF1 chr3:12626632 NM_002880 c.1657A>C N553H rs745876012 4.06x10-
6
HCM SI, PR, PP2,
MT, PC, PP
RYR2 chr1:237802395 NM_001035 c.7009G>C G2337R - - ARVC GS, SI, PR,
PP2, MT, PC,
PP
TNNT2 chr1:201334425 NM_001276345 c.305G>A R102Q rs121964856 - HCM SI, PR, PP2,
MT, PC, PP,
CV, HG
(Continued )
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potentially pathogenic variants involving DMD and OBSCN genes, not previously associated
with this phenotype. Indeed, we found one novel potentially pathogenic missense variant in
DMD gene in patient identified as 1751ARVC (DMD_R1320H) and one potentially patho-
genic missense variant in OBSCN gene.
Regarding the HCM phenotype, we identified two potentially pathogenic variants involving
DLG1 and AKAP9 genes, not previously associated with this phenotype. In DLG1 gene, a
potentially pathogenic missense variant was found in patient identified as 1776HCM (DLG1_
G639R); in AKAP9 gene, a novel potentially pathogenic nonsense variant was found in patient
identified as 1833HCM (AKAP9_Y3870X).
With regard to DCM, the association between potentially disease-causing variants in
OBSCN gene and this phenotype was recently described [54]. Our findings were in agreement
with this new association, as we found two potentially pathogenic variants in OBSCN gene,
one in patient identified as 682DCM (OBSCN_R6669H) and the other in patient identified as
1718DCM (OBSCN_A5660V). Moreover, for DCM phenotype, we identified one potentially
pathogenic variant involving the AKAP9 gene, not previously associated with DCM, in patient
identified as 76DCM (AKAP9_R3435X).
Discussion
The technology of NGS is now emerging as a powerful approach to comprehensively explore
genetic mutations in a wide range of human pathologies [36, 55]. In this study, we used tar-
geted resequencing to identify novel genetic variations associated with three inherited cardio-
myopathies, namely HCM, DCM, and ARVC, which are common causes of mortality before
the fifth decade of life. These inherited cardiomyopathies are genetically heterogeneous and
are associated with rare mutations in a large number of genes, many of which overlap among
the phenotypes. Moreover, considerable phenotypic and genetic overlaps between cardiomy-
opathies and arrhythmic syndromes have been documented [22–29]. Considering these over-
laps, our study aimed to look for new potential gene–phenotype associations with a view to
expand the mutational spectrum underlying cardiomyopathies, with possible implications for
better diagnosis and clinical management. We designed a custom gene panel including 115
genes, known to be associated with the three cardiomyopathic phenotypes and/or arrhythmic
syndromes. Using this panel, we performed molecular screening of a cohort of 38 unrelated
patients affected by cardiomyopathies (16 DCM, 14 HCM, and 8 ARVC). Overall, our analysis
identified a total of 142 rare variants in 40 genes and confirmed 11 rare variants (ACTC1_S236F,
LAMP2_V310I, LMNA_Leu140-Ala146dup, LMNA_Q517X, MYBPC3_A364T,MYBPC3_c.821
+1G>A, MYBPC3_E728X,MYH7_A1763T, MYH7_G701D, MYL2_E134A, and TNNT2_
R102Q) which we previously identified in some of our patients by Sanger sequencing [52, 56],
thereby demonstrating that our approach, that combined NGS and different in silico prediction
Table 1. (Continued)
Gene Genomic
Position
Transcript Nucleotide Protein dbSNP MAF Cardiac
Phenotype
Supporting
evidences
TTN chr2:179434235 NM_003319 c.49429delG V16477fs - - DCM MT, PC, PP
Last revised May 2017. MAF: minor allele frequency in gnomAD; GS: Grantham’s score>100; SI: classified as “Dangerous” by SIFT; PR: classified as
“Deleterious” by PROVEAN; PP2: classified as “Problably Damaging” or “Possibly Damaging” by PolyPhen2; MT: classified as “Disease Causing” by
Mutation Taster; PC: PhastCons score = 1; PP: PhyloP score>1; CV: classified as “Pathogenic” in ClinVar in association with the same cardiac phenotype;
HG: described in HGMD in association with the same cardiac phenotype; REF: published data supporting the variant pathogenicity. Genomic coordinates
are referred to the hg19 version of the human genome.
https://doi.org/10.1371/journal.pone.0181842.t001
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Table 2. Genetic profile of each cardiomyopathic patient carrying potentially pathogenic rare variants.
Patient Gene Genomic
Position
Transcript Nucleotide Protein
76DCM
AKAP9 chr7:91726576 NM_005751 c.10303C>T R3435X
DSP chr6:7569522 NM_004415 c.1524dupG V508fs
99DCM
TTN chr2:179434235 NM_003319 c.49429delG V16477fs
682DCM
OBSCN chr1:228557681 NM_001098623 c.20006G>A R6669H
737DCM
LMNA chr1:156100468 NM_170708 c.667_687dup L140_A146dup
1060DCM
DSP chr6:7580243 NM_004415 c.3820G>C A1274P
1329DCM
MYH7 chr14:23884353 NM_000257 c.5410G>A A1804T
1718DCM
OBSCN chr1:228525823 NM_001098623 c.16979C>T A5660V
1801DCM
MYH7 chr14:23886383 NM_000257 c.4498C>T R1500W
1816DCM
LMNA chr1:156106964 NM_170708 c.1549C>T Q517X
1173HCM
MYBPC3 chr11:47360197 NM_000256 c.2182G>T E728X
OBSCN chr1:228400286 NM_052843 c.802G>T E268X
1657HCM
MYBPC3 chr11:47371475 NM_000256 c.506-2A>C -
1661HCM
MYBPC3 chr11:47371475 NM_000256 c.506-2A>C -
1674HCM
NEXN chr1:78401657 NM_144573 c.1398_1400delAAT I467del
1699HCM
MYBPC3 chr11:47369407 NM_000256 c.821+1G>A -
1721HCM
RAF1 chr3:12626632 NM_002880 c.1657A>C N553H
1739HCM
TNNT2 chr1:201334425 NM_001276345 c.305G>A R102Q
1740HCM
LAMP2 chrX:119576454 NM_013995 c.928G>A V310I
1741HCM
ACTC1 chr15:35084392 NM_005159 c.707C>T S236F
1776HCM
DLG1 chr3:196812473 NM_004087 c.1915G>A G639R
MYBPC3 chr11:47367758 NM_000256 c.1090G>A A364T
1832HCM
MYH7 chr14:23895233 NM_000257 c.2102G>A G701D
1833HCM
AKAP9 chr7:91737871 NM_005751 c.11610C>G Y3870X
1662ARVC
(Continued )
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tools, was both reliable and sensitive at identifying rare variants. Interestingly, for 75 genes in
our panel, no rare variant was identified, suggesting that some gene–phenotype associations
reported in the literature (on which our gene panel was based) are restricted to unique or few
cases.
Our results confirm previous data indicating that cardiomyopathic patients could carry
multiple specific genetic variants [33, 34, 57]. In fact, we found on average more than three
rare variants per proband, with DCM patients carrying the highest average number of rare var-
iants, followed by HCM and ARVC patients. Furthermore, since our subjects were selected on
the basis of phenotype severity and family history of cardiomyopathy and/or SD, our results
support the evidence that multiple mutations are likely to elicit a more severe phenotype.
Table 2. (Continued)
Patient Gene Genomic
Position
Transcript Nucleotide Protein
OBSCN chr1:228527758 NM_001098623 c.17371G>C A5791P
1666ARVC
PKP2 chr12:32974392 NM_004572 c.2043delT I681fs
1751ARVC
DMD chrX:32456458 NM_004009 c.3959G>A R1320H
1812ARVC
RYR2 chr1:237802395 NM_001035 c.7009G>C G2337R
1825ARVC
PKP2 chr12:33030842 NM_004572 c.962_972del
TCGGCCAGGCG
V321GfsX11
New gene-phenotype associations are in bold characters.
https://doi.org/10.1371/journal.pone.0181842.t002
Fig 1. New gene–phenotype associations and number of novel gene rare variants for each cardiomyopathic phenotype.
https://doi.org/10.1371/journal.pone.0181842.g001
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Indeed, previous studies suggested that patients carrying multiple mutations are more likely to
develop the disease at an early age and with more severe clinical features, as poor prognoses
are associated with compound or double heterozygotes [33, 34].
Titin is the largest described human protein, constituting one of the most abundant types of
filaments in both cardiac and skeletal muscle and plays a central role in sarcomere organiza-
tion. TTN has been recognized as the main disease-causing gene in DCM and is also involved
in the pathogenesis of HCM and ARVC [17, 49, 58]. Our study confirmed the high prevalence
of TTN rare variants in cardiomyopathies, most of which are missense. TTNmissense variants
are very common and often frequently benign and it was reported that TTNmissense variants
bioinformatically classified as “severe” did not associate with differences in clinical phenotypes
in DCM patients, so arguing that many TTNmissense variants are not disease-causing variants
[48]. For these reasons, many TTNmissense variants identified in our study were not classified
as potentially pathogenic, despite the results of predictors’ analysis. Regarding TTN truncating
variants, recent studies supported that not all these variants are equals in terms of clinical rele-
vance. In particular, the TTN truncating variants with the highest probability of pathogenicity
are those affecting TTN isoforms in the A-band region [50, 51]. In our study, we identified
three TTN truncating variants in DCM patients: V16477fs (referred to NM_003319 transcript),
L24944X (referred to NM_003319 transcript) and R2490fs (referred to NM_133379 tran-
script). According to recent evidences, we considered as potentially pathogenic, with a possible
clinical relevance, only the V16477fs variant, as it maps in the A-band region and affects all
TTN transcripts. However, it cannot be ruled out that multiple variants (missense and truncat-
ing) on the TTN protein may have a cumulative effect on a cardiomyopathic phenotype.
In this study, we extended the number of overlapping genes among cardiomyopathies and
also between cardiomyopathies and arrhythmic syndromes, identifying novel potential gene-
phenotype associations (Fig 1 and S2 Table). As reported in Fig 2, which shows the distribution
of specific and overlapping genes carrying rare variants identified in this study, among the
three cardiomyopathic phenotypes, we detected five genes (DMD, OBSCN, SYNE1, TNNC1,
VCL) carrying rare variants in the three phenotypes, six genes (AKAP9, CACNA1C, CHRM2,
DLG1, MYO6, PSEN2) carrying rare variants in HCM and DCM, and one gene (TRPM4)
carrying rare variants in ARVC and DCM. As several patients carried variants in genes not
previously related to their phenotype, the use of our “pan-cardiomyopathy panel” may prove
beneficial to identify the novel potential gene-phenotype associations. In fact, a phenotype-
specific targeted gene testing [30] might miss to identify several variants in cardiomyopathic
patients. Conversely, a comprehensive gene testing could enhance the diagnostic and prognos-
tic implications of genetic screening by not only allowing an early diagnosis of inherited cardi-
omyopathic forms but also by contributing to a more accurate prognostic stratification and
patient management [31].
OBSCN variants were firstly described in HCM patients [59] and, more recently, OBSCN
variants associated with DCM and Left Ventricular Noncompaction patients were reported
[54, 60]. Our results are in agreement with the association between OBSCN gene variants and
DCM phenotype, since we found eight different rare variants in 8 DCM patients. When our
analysis was restricted to potentially pathogenic variants, the association between OBSCN vari-
ants and DCM remained, because two potentially pathogenic variants, OBSCN_R6669H and
OBSCN_A5660V, were detected in patients identified as 682DCM and 1718DCM, respectively
(Table 2). Furthermore, for the first time to our knowledge a possible association between
OBSCN gene and the ARVC phenotype is evidenced. In fact, we found three different OBSCN
rare variants in two out of eight ARVC probands. One of these variants, OBSCN_A5791P was
classified as potentially pathogenic (Table 1 and S11 Table) and was detected in patient identi-
fied as 1662ARVC (Table 2). A possible pathogenic role for OBSCN variants detected in some
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of our DCM and ARVC patients is supported by the fact that these variants involve OBSCN
domains having functional and/or structural importance and affect highly conserved amino
acid regions across species. Obscurin is a member of a family of giant proteins that is expressed
in striated muscle and interacts with titin, myomesin and small ankyrin-1 and has been pro-
posed to be a structural protein linking the M-line of the sarcomere to the sarcoplasmatic retic-
ulum [61, 62]. Different obscurin isoforms are known: obscurin A (~720 kDa); obscurin B
(~870 kDa), which is similar to obscurin A but lacking the nonmodular COOH-terminal re-
gion and including two Ser/Thr kinase domains, called SK2 and SK1; and two smaller obscurin
isoforms, one containing a full-length SK1 and a partial SK2 and the other containing only the
SK1 domain. The expression of these obscurin isoforms differs; while giant obscurins A and B
are expressed in higher amounts in skeletal muscle, the tandem and single kinase isoforms
are largely present in cardiac muscle [62]. Variant OBSCN_R6669H involves the SK1 domain,
and variant OBSCN_A5791P falls in a functionally important domain of obscurin, the tandem
Rho-guanidine nucleotide exchange factor (RhoGEF) present in Rho/Rac/Cdc42-like GTPases,
and thus these variants may affect obscurin cell signaling pathways. Variant OBSCN_A5660V
is present in the src homology-3 (SH3)-conserved domain, a protein interaction domain. There-
fore, OBSCN appears to be a good candidate gene for both DCM and ARVC phenotypes. Re-
cent data supported OBSCNmutations as a significant causal factor for DCM pathogenesis,
reporting that disease-related OBSCNmutations cause haploinsufficiency that accounts for the
development of the DCM phenotype [54]. Moreover, it was suggested that OBSCNmutations
could act alone or in concert with other mutations, contributing to cause DCM [54, 63]. Our
data are in agreement with this last hypothesis, since patients carrying a potentially pathogenic
Fig 2. Distribution of specific and overlapping genes carrying rare variants identified in this study,
among the three cardiomyopathic phenotypes.
https://doi.org/10.1371/journal.pone.0181842.g002
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variant in the OBSCN gene also carried other rare variants in different genes, such as PKP2, or
TTN, suggesting a possible cumulative effect on cardiomyopathic phenotype.
For the ARVC phenotype, we also found an association with the DMD gene. Mutations in
the DMD gene, encoding for dystrophin, are responsible for X-linked DCM and myopathies
[64–66]. ARVC patients were found to be affected by myofibrillar myopathy [67, 68], facio-sca-
pulo-humeral muscular dystrophy [69], and myotonic dystrophy type 1 [70]. An ARVC-like
phenotype was described in desmin-related myopathy [71] and myotonic dystrophy type 1 [72].
In addition, some of the genes recently found to be associated with ARVC are also responsible
for myopathies/muscular dystrophies, such as DES [73], LDB3 [74], and TTN [75]. Moreover,
both phenotypic and genetic overlaps between DCM and ARVC were observed [52, 75–77].
We identified the DMD_R1320H variant in the patient identified as 1751ARVC, who was
diagnosed with ARVC and associated LV systolic dysfunction at the age of 42 years. The novel
variant is localized in the spectrin domain number 9 of dystrophin and is predicted to be path-
ogenic in silico because it is believed to affect two DMD transcripts. Mutations in dystrophin
affecting the plasma membrane and causing myofiber loss could lead to the pathologic sub-
strate favoring myocardial atrophy and fibrofatty replacement, which are the main pathoge-
netic mechanisms described in ARVC [78]. However, more evidences are necessary to
consider DMD as a new gene associated with the ARVC phenotype.
Although hereditary cardiomyopathies and arrhythmic syndromes are considered distinct
groups of genetic disorders, a considerable phenotypic overlap between these two apparently
distinct cardiac disorders has been documented. In fact, the clinical cardiomyopathic picture
often includes a wide range of features related to arrhythmias and conduction abnormalities;
conversely, ion channel defects linked to arrhythmic syndromes may be associated with mor-
phological changes and structural abnormalities that characterize some types of cardiomyopa-
thy [5, 24–29, 79]. In a recent study that screened HCM probands for both sarcomere and
non-sarcomere protein gene mutations, ANK2, PLN, and SCN5A gene variants were suggested
to have modifying effects on HCM phenotypic expression [26]. Moreover, novel associations
between three genes (KCNQ1, KCNH2, and KCNE2) associated with Long QT syndrome and
HCM phenotype were proposed [26]. As the main goal of our study was to look for new gene–
phenotype associations, we included in our custom panel some genes associated with inherited
arrhythmic syndromes in order to support the evidence that genes implicated in channelopa-
thies could modify the clinical characteristics and severity of cardiomyopathic phenotypes.
We found novel potential gene–phenotype associations between genes typically related to
arrhythmic syndromes (AKAP9, ANK2, CACNA1C, DLG1, HCN4, KCNJ8, NUP155 and
TRPM4 genes) and the cardiomyopathic phenotypes discussed in our study (S2, S9 and S11
Tables). In particular, focusing on the potentially pathogenic variants, we detected new associ-
ations between AKAP9 variants and both DCM and HCM and between DLG1 variant and
HCM (Table 2 and S11 Table).
A novel association between AKAP9 gene and DCM was observed in patient identified as
76DCM. This patient demonstrated an early-onset (15 years) DCM phenotype and presented
with a history of palpitations, syncope on effort, and evidence of frequent multifocal premature
ventricular complexes, non-sustained VT episodes, and atrioventricular conduction abnormali-
ties recorded on Holter monitoring. He received an ICD. During follow-up, he suffered from
recurrent episodes of sustained VT and VF discontinued by ICD shocks. This patient carried
two potentially pathogenic variants: DSP_V508fs variants and AKAP9_R3435X (Table 2 and
S11 Table). DSP_V508fs is a novel variant, predicted to produce a truncated protein and to
reduce DSP expression. AKAP9_R3435X is predicted to produce a truncated protein from three
different AKAP9 transcripts, thus suggesting either a dominant negative mechanism or a non-
sense-mediated mRNA decay mechanism. We suppose that the DSP_V508fs variant is the
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primary disease-causing mutant since the DSP gene has been demonstrated to be associated
with DCM (OMIM: 615821) and biventricular arrhythmogenic cardiomyopathy (OMIM:
607450) and that AKAP9may be a modifying gene causing severe ventricular tachyarrhythmias,
such as those occurring in the patient identified as 76DCM. This hypothesis is supported by the
evidence that AKAP9 has been considered as a genetic modifier of congenital LQTS, increasing
cardiac risk and disease severity in AKAP9mutation carriers [80].
Another potentially pathogenic variant (AKAP9_Y3870X) is present in the patient identi-
fied as 1833HCM, who also carries the MYL2_E134A variant (S10 Table). The MYL2 variant
may have a pathogenic role in 1833HCM patient, as previously described for the same pheno-
type [81], although it is classified as VUS in ClinVar database. The AKAP9_Y3870X variant
may act as a disease severity modifier, even though the stop codon introduced by this mutation
is located in the C-terminal part of the protein; so, its effect should be analyzed in functional
studies and/or segregation in families.
DLG1 encodes the synapse-associated protein 97 protein (SAP97), a protein belonging to
the membrane-associated guanylate kinase (MAGUK) family of proteins that are important for
localization and organization of ion channels. SAP97 interacts with and modulates cardiac Kv4.3
channels that account for a large part of the transient outward potassium current (Ito) [82], but
also binds and regulates the expression of NaV1.5, the main cardiac inward sodium channel
[83]. Both channels are implicated in Brugada syndrome (BRGDA1, OMIM: 601144; BRGDA9,
OMIM: 616399), and consequently a DLG1 variant may confer susceptibility to arrhythmias as
demonstrated by a putative DLG1 pathogenic mutation in a patient affected by this syndrome
[84]. We found the potentially pathogenic variant DLG1_G639R in patient identified as 1776
HCM, also carrying the potentially pathogenic variant MYBPC3_A364T (Table 2, S10 and
S11 Tables). The MYBPC3_A364T variant may be considered pathogenic for this patient, as
MYBPC3 is one of the main genes associated with HCM. The DLG1_G639R variant involves the
DLG1 SH3 domain, which mediates the assembly of specific protein complexes via binding to
proline-rich peptides. It is conceivable that this mutation could affect DLG1-Kv4.3 or DLG1-
NaV1.5 interactions, modulating their functions and favoring susceptibility for arrhythmias.
Our study demonstrates that a targeted resequencing approach can provide a relevant sup-
port for a genetic diagnosis in cardiomyopathic patients. However, in many patients, in partic-
ular, those affected by DCM, it was not possible to obtain a clear genetic diagnosis on the basis
of our gene panel, thus suggesting a greater genetic heterogeneity in this cardiomyopathy
respect to the others and/or a considerable role of modifier genes in determining this pheno-
type. Gene discovery by whole exome or genome sequencing would be required for those pro-
bands that are still without a molecular diagnosis. However, the application of this approach
would make the interpretation of genetic screening results difficult for clinical purposes due to
the large amount of sequencing data that need to be analysed.
We are aware that our study would need to be supported by evidences in favor of a patho-
genic role of the variants reported here (e.g., lack of segregation analysis due to sporadic car-
diomyopathy, and/or unavailability and/or small number of relatives available for genetic
investigations and lack of functional studies) [85], not allowing us to assess the clinical rele-
vance of the identified variants. Segregation analysis together with functional studies may con-
cur to establish a more definite diagnosis, allowing the findings to be interpreted in the context
of a clinical setting. However, families with multiple affected individuals are a rare occurrence
and often a novel variant is present in a single individual with only few or no other clinically
affected relatives. Consequently, many novel NGS variants are classified as VUS and cannot
represent a conclusive test result at present, as recently highlighted [85].
On the other hand, we believe that the rigorous approaches used in this study to identify
the cardiomyopathies associated variants (e.g. recruitment of patients with more severe
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phenotypes and family history of cardiomyopathy and/or sudden death, selection of variants
using a MAF lower than the frequency of each cardiomyopathy, application of different in
silico prediction tools to select the potentially pathogenic variants) reliably support our hypoth-
esis that many of them may contribute to cardiomyopathy development and/or its progres-
sion. In particular, in agreement with results obtained by Marston et al. [54], mutations in the
OBSCN gene could be considered a significant causal factor, alone or in concert with other
mutations, for DCM and ARVC pathogenesis. Furthermore, variants in AKAP9 and DLG1
genes could act as genetic modifiers of arrhythmic risk and phenotype severity in cardiomyop-
athies. In addition, variants of unknown pathogenicity, sometimes complicating the clinical
picture, may contribute to the disease development and/or may have modifier effects. It is pos-
sible to hypothesize that the genetic component underlying cardiomyopathic phenotypes and/
or modifying disease phenotype severity could be explained by the cumulative functional
effects of coding and non-coding DNA variants.
To conclude, this work highlights the challenges faced in the diagnosis of cardiomyopathies.
NGS is a highly accurate and reproducible approach for routine molecular screening of
patients with cardiomyopathies, but the identification of genetic defects in the proband is not
sufficient in isolation for clinical decision-making or genetic counselling.
Finally, our data support the remarkable contribution that a targeted NGS approach could
offer to genetic overlap knowledge between different cardiomyopathies, expanding previous
results and ameliorating molecular diagnosis.
In the brackets, we report the number of the new potential gene-phenotype associations
(number on the left) and the number of the overlapping genes (number on the right) detected
in this study (see also underlined associations in S2 Table).
Supporting information
S1 Fig. Variant classification.
A. Missense, stop-gain, stop-loss and splice site variant analysis. Single nucleotide variant
calls supported by at least 10 reads and with a minor allele frequency 0.004, 0.002 and
0.0005 for DCM, HCM and ARVC patients respectively in variant databases, were considered.
Missense variants were analyzed using Mutation taster, SIFT, Provean and Polyphen-2 and
retained if predicted to be “disease causing” by Mutation Taster, “damaging” by SIFT, “deleteri-
ous” by Provean and “probably” or “possibly damaging” by Polyphen-2 and considered Poten-
tially Pathogenic missense variants if not classified as VUS, Likely Benign or Benign in ClinVar
database. Stop-gain, stop-loss and splicing site variants were analyzed using Mutation Taster and
considered Potentially Pathogenic radical variants if predicted to be “disease causing” and if not
classified as VUS, Likely Benign or Benign in ClinVar database.
B. Insertion/deletion variant analysis. Frameshift and in-frame insertion/deletion variants sup-
ported by at least 10 reads with a minor allele frequency 0.004, 0.002 and 0.0005 for DCM,
HCM and ARVC patients respectively in variant databases, were considered and classified as rare
radical variants. Radical variants were analyzed using Mutation Taster and considered Potentially
Pathogenic if predicted to be “disease causing” and if not classified as VUS, Likely Benign or
Benign in ClinVar database.
Missense and radical variants were also considered as Potentially Pathogenic variants, indepen-
dently from the results obtained with the above predictors, if classified as “Pathogenic” or “Likely
Pathogenic” in published data and/or in ClinVar or HGMD database, in association with cardio-
myopathies. TTNmissense variants were not considered potentially pathogenic independently
from predictors’ responses. TTN truncating variants were considered potentially pathogenic if
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they affected all TTN isoforms in the A-band region.
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